3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one: stimulates arginine vasopressin secretion; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9799188 |
| CHEMBL ID | 378873 |
| SCHEMBL ID | 580196 |
| MeSH ID | M0379871 |
| Synonym |
|---|
| CHEMBL378873 |
| 2-cyclohexen-1-one, 3-(15-hydroxypentadecyl)-2,4,4-trimethyl- |
| 220757-88-0 |
| SCHEMBL580196 |
| 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one |
| FGMAOXGOTRUOKJ-UHFFFAOYSA-N |
| DTXSID30430917 |
| AKOS030527076 |
| tcfa15 |
| HY-104031 |
| CS-0025935 |
| 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one |
| 3-(15-hydroxypentadecyl)-2,4,4-trimethylcyclohex-2-en-1-one |
| MS-25821 |
| 3-(15-hydroxypentadecyl)-2,4,4-trimethylcyclohex-2-enone |
| VIA75788 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, the clinical use of these proteic factors is still restricted, and brings about undesirable consequences, including adverse side effects, and bioavailability and stability difficulties." | ( Neurotrophic activity of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one in cultured central nervous system neurons. Coowar, D; Duportail, G; Girlanda-Junges, C; Gonzalez de Aguilar, JL; Loeffler, JP; Luu, B, 2001) | 0.31 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, similar drug treatments and dosing in 7-day postoperative neuropathic pain model rats (prepared by the method of Bennett and Xie) yielded a similarly favorable outcome by significantly reversing decreased nociceptive thresholds in the paw pressure test." | ( Beneficial action of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one, a novel long-chain fatty alcohol, on diabetic hypoalgesia and neuropathic hyperalgesia. Koyama, K; Monden, M; Shiomi, H; Suzuki, H; Tamura, Y; Yamada, M, 2006) | 0.33 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID264679 | Growth promoting activity in axon at 100 nM in presence of 10 ug/ml myelin protein of glial scar | 2006 | Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10 | Quinol fatty alcohols as promoters of axonal growth. |
| AID264673 | Hydroxyl radical scavenging activity by ABTS assay | 2006 | Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10 | Quinol fatty alcohols as promoters of axonal growth. |
| AID264677 | Growth promoting activity in axon at 100 nM in presence of 1 ug/ml myelin protein of glial scar | 2006 | Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10 | Quinol fatty alcohols as promoters of axonal growth. |
| AID264674 | Growth promoting activity in axon relative to control | 2006 | Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10 | Quinol fatty alcohols as promoters of axonal growth. |
| AID281656 | Hydroxyl radical scavenging activity after 2 hrs by ABTS competition assay | 2004 | Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25 | Effects of indole fatty alcohols on the differentiation of neural stem cell derived neurospheres. |
| AID264675 | Growth promoting activity in axon at 100 nM | 2006 | Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10 | Quinol fatty alcohols as promoters of axonal growth. |
| AID264681 | Growth promoting activity in axon at 100 nM in presence of 100 ng/ml Sema3A of glial scar | 2006 | Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10 | Quinol fatty alcohols as promoters of axonal growth. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (85.71) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||